Evidence map›Paper›PMID 40593888›Full record

ArticleScientific reports2025

Systematic screening for primary immunodeficiencies in patients hospitalized for severe infection in pediatric intensive care unit.

Anna Deguet, Marie-Gabrielle Vigue, Claire Lozano, Julien Baleine, Christophe Milesi, Anne Sirvent, Laura Kollen, Léa Domitien, Marjolaine Willems, Jean Donadieu and 11 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Anna DeguetDepartment of Pediatrics, CHU Montpellier, Hôpital Arnaud de Villeneuve, 371 avenue du Doyen Gaston Giraud, 34295, Montpellier Cedex 5, France. a-deguet@chu-montpellier.fr.
Marie-Gabrielle VigueDepartment of Pediatrics, CHU Montpellier, Hôpital Arnaud de Villeneuve, 371 avenue du Doyen Gaston Giraud, 34295, Montpellier Cedex 5, France.
Claire LozanoDepartment of Immunology, CHU Montpellier, Montpellier, France.
Julien BaleinePediatric Resuscitation Department, CHU Montpellier, Montpellier, France.
Christophe MilesiPediatric Resuscitation Department, CHU Montpellier, Montpellier, France.
Anne SirventPediatric Haematology and Oncology Department, CHU Montpellier, Montpellier, France.
Laura KollenPediatric Gastroenterology Department, CHU Montpellier, Montpellier, France.
Léa DomitienDepartment of Pediatrics, CHU Montpellier, Hôpital Arnaud de Villeneuve, 371 avenue du Doyen Gaston Giraud, 34295, Montpellier Cedex 5, France.
Marjolaine WillemsMedical Genetics Department, INSERM U1298, Reference Centre AD SOOR, AnDDI-RARE, CHU, University of Montpellier, Montpellier, France.
Jean DonadieuPediatric Hematology and Oncology Department, Trousseau Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Christine Bellané-ChantelotMedical Genetics Department, Pitié Salpetrière Hospital, APHP, Paris, France.
Federica DefendiDepartment of Immunology, CHU Grenoble-Alpes, Grenoble, France.
Carine El SissyDepartment of Immunology, Paris University, Hôpital Européen Georges-Pompidou, APHP, Paris, France.
Anne SpraulBiochemistry Department, CHU Bicêtre, APHP, Paris-Saclay University, Le Kremlin-Bicêtre, France.
Jérémie RosainStudy Center for Primary Immunodeficiencies, Necker Hospital for Sick Children, AP-HP, Laboratory of Human Genetics of Infectious Diseases, Inserm U1163, Paris Cité University, Imagine Institute, Paris, France.
Capucine PicardStudy Center for Primary Immunodeficiencies, Necker Hospital for Sick Children, AP-HP, Paris, France.
Joana PissarraClinical Research and Epidemiology Unit, CHU Montpellier, Univ Montpellier, Montpellier, France.
Caroline MolleviInstitute Desbrest of Epidemiology and Public Health, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, France.
Fanchon HermanClinical Research and Epidemiology Unit, CHU Montpellier, Univ Montpellier, Montpellier, France.
Jacinta BustamanteStudy Center for Primary Immunodeficiencies, Necker Hospital for Sick Children, AP-HP, Laboratory of Human Genetics of Infectious Diseases, Inserm U1163, Paris Cité University, Imagine Institute, Paris, France.
Eric JeziorskiDepartment of Pediatrics, CHU Montpellier, Hôpital Arnaud de Villeneuve, 371 avenue du Doyen Gaston Giraud, 34295, Montpellier Cedex 5, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over 500 primary immunodeficiency diseases (PID) have been described, but immunological assessment after a severe infection is not routine. We aimed to evaluate the feasibility of a PID screening protocol and calculate PID prevalence in children admitted for severe infection in a pediatric intensive care unit (PICU). This monocentric retrospective study evaluated the feasibility of a PID monitoring protocol after severe infection in children aged 1 month to 16 years-old hospitalized in the Montpellier University Hospital from January 2018 to December 2020. Follow-up consultations at 3 and 12 months included the three main PID screening scores, comprehensive immunological and genetic screenings. Among 1125 children admitted to the PICU, 46 had severe infections and caused by bacterial (48%), viral (39%) or fungal (2%) pathogens. Before infection, none had completed any screening score recommended by dedicated societies (Jeffrey Modell Foundation, German Patients' Organization for Primary Immunodeficiencies, French Reference Center for Hereditary Immunodeficiencies). At 3 months, three patients had a PID diagnosis (6.5% prevalence, 95% CI 1.4-17.9). These were associated with a deletion of chromosomal region 22q11.21 (DiGeorge syndrome), ELANE mutation (Elastase deficiency or Severe Congenital Neutropenia 1), and C5 deficiency Forty children (87%) presented immunological anomalies without a formal PID diagnosis. These persisted in only 4/17 children tested at 12 months. The most frequent abnormalities were low NK lymphocytes (41.18%), and abnormal B lymphocyte population distribution (25%). The observed PID prevalence post-severe infection matches previous reports, even with a high rate of viral infections, often overlooked. Systematic PID investigation after severe infection, regardless of the pathogen, should be implemented to improve early detection and treatment.

Indexed as

Immunologic Deficiency SyndromesInfectionsIntensive Care Units, PediatricPrimary Immunodeficiency DiseasesAdolescentChildChild, PreschoolFemaleHospitalizationHumansInfantMaleMass ScreeningPrevalenceRetrospective StudiesChildGenetic testingInfectionIntensive care unitsPediatricPrimary immunodeficiency diseasesPrognosis

Identifiers

PMID40593888
PMCPMC12214530

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.